Boehringer breathes easier as TIOSPIR 'confirms Respimat safety'
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has presented the results of the TIOSPIR (Tiotropium Safety and Performance in Respimat) study which demonstrate the non-inferiority of tiotropium delivered as a mist via the Respimat inhaler compared to the older Spiriva HandiHaler (tiotropium powder) on all-cause mortality outcomes in COPD patients.